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Abstract
Background: Hypothyroidism following radiation therapy (RT) for treatment of Head and Neck Cancer (HNC) is a
common occurrence. Rates of hypothyroidism following RT for Early Stage Laryngeal Squamous Cell Carcinoma
(ES-LSCC) are among the highest. Although routine screening for hypothyroidism is recommended; its optimal
schedule has not yet been established. We aim to determine the prevalence and optimal timing of testing for
hypothyroidism in ES-LSCC treated with RT.
Method: We conducted a population-based cohort study. Data was extracted from a prospective provincial head
and neck cancer database. Demographic, survival data, and pre- and post-treatment thyroid stimulating hormone
(TSH) levels were obtained for patients diagnosed with ES-LSCC from 2008–2012. Inclusion criteria consisted of
patients diagnosed clinically with ES-LSCC (T1 or 2, N0, M0) treated with curative intent. Patients were excluded if
there was a history of hypothyroidism before the treatment or any previous history of head and neck cancers.
Results: Ninety-five patients were included in this study. Mean age was 66.1 years (range: 44.0–88.0 years) and
82.3 % of patients were male. Glottis was the most common subsite at 77.9 % and the average follow-up was
40 months (Range: 12–56 months). Five-year overall survival generated using the Kaplan-Meier method was 79 %.
Incidence of hypothyroidism after RT was found to be 46.9 %. The greatest frequency of developing hypothyroidism
was at 12 months.
Conclusions: We found a high prevalence of hypothyroidism for ES-LSCC treated with RT, with the highest rate at
12 months. Consequently, we recommend possible routine screening for hypothyroidism using TSH level starting at
12 months. To our knowledge, this is the first study to suggest the optimal timing for the detection of hypothyroidism.
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Introduction
Head and neck cancer (HNC) encompasses 3 % of total
malignancies in North America, with a large proportion
presenting as laryngeal squamous cell carcinoma (LSCC)
[1]. One thousand and fifty cases were diagnosed alone
in Canada in 2014 [2]. Treatment for early stage LSCC
(ES-LSCC) has traditionally utilized single modality re-
gimes consisting of either radiation therapy (RT) or
surgical resection [3, 4]. Due to increasing advances in
radiation planning over the past decade using computer-
ized tomography based image planning, many cancer
treatment centers including ours have adopted RT as the
preferred method of treatment for ES-LSCC [5].
Despite improvements in RT therapy, its effects on the
thyroid gland remains significant, as it is located in very
close proximity to the target of treatment [6, 7].
Hypothyroidism as the result of radiation induced fibrosis
and compromise of thyroid vascularity is still a common
unnoticed complication after treatment of LSCC with a
frequency of 14–36 % [8]. The most common signs and
symptoms of hypothyroidism present as dry skin, cold sen-
sitivity, fatigue, muscle cramps, voice changes, and consti-
pation [9]. Left untreated hypothyroidism is associated
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with increased total low-density lipoprotein cholesterol
and cardiac morbidity including mortality and atheroscler-
otic events [10]. As a result of these risks, the NCCN
guidelines recognise the risk of developing hypothyroidism
in association with treatments for LSCC and recommend
screening every 6 to 12 months following treatment [11].
However, to our knowledge there has been no conclusive
evidence looking at the optimal time in screening for
hypothyroidism for ES-LSCC treated with RT. Therefore,
we sought to investigate the ideal time of testing for
hypothyroidism in patients with ES-LSCC treated with RT
defined as the point in time where the test is associated
with the highest frequency. We also evaluated the inci-
dence of hypothyroidism in this patient population within
Alberta, Canada.
Method
Ethics approval was granted by the University of Alberta’s
Health Research Ethics Board (HREB) and the Alberta
Cancer Board.
Patients
Inclusion criteria were defined as: residents of Alberta
greater than 18 years of age, with biopsy-proven early
stage (T1 or T2, N0) LSCC (based on the 7th Edition of
the AJCC TNM Staging Manual) [12]. All treated using
primary RT with curative intent in Alberta.
Exclusion criteria were defined as: patients with previ-
ous HNC with or without treatment, a diagnosis of
hypothyroidism prior to radiation treatment or incom-
plete data sets from chart review.
Data collection
All patients diagnosed with ES-LSCC meeting inclusion
criteria from January 1, 2008 to December 31, 2012 were
included in the study. Demographic, survival and clini-
copathologic data was obtained initially through the
Alberta Cancer Registry (ACR) by a data analyst. The
ACR is a population-based registry established in 1942
that records and maintains data of all new cancer cases,
their treatments, and resulting deaths in the province of
Alberta in a longitudinal and prospective fashion [13]. A
review of outpatient, inpatient, and cancer clinic records
was then performed for quality assurance and to extract
relevant patient, tumour, lab values (pre-treatment albu-
min and pre and post-treatment thyroid stimulating hor-
mone (TSH) levels), treatment, follow-up, as well as
survival data Charlson Comorbidity Index (CCI) scores,
which were not included in the ACR database, were cal-
culated using relevant comorbidities taken from chart
review [14]. Date of diagnosis was defined as the date of
pathologically confirmed ES-LSCC.
Staging
Staging of the tumours was clinical and according to the
seventh edition of the American Joint Committee on
Cancer (AJCC) TNM staging manual [12].
Treatment
All patients underwent radiation therapy (RT) for cura-
tive intent. Patients receiving RT or CRT for distant
metastases or palliation were not included. Intensity-
modulated or 3-D conformal RT were utilized with
dosing between 60.75 and 70 Gy, using 2 Gy per frac-
tion, depending on the T-status [11].
Outcomes
The primary outcome was set as the optimal time of
testing for the elevation of TSH after treatment of ES-
LSCC defined as the point in time where the testing is
the most sensitive. The time interval to the initial eleva-
tion of TSH after treatment of ES-LSCC with RT was
calculated for every patient. This was defined as the time
from completion of RT until the first elevated TSH. The
secondary outcome was the incidence of hypothyroidism
after treatment of ES-LSCC with RT.
Hypothyroidism
All included patients had pre-treatment TSH values.
Patients were then screened for elevated TSH levels at
3–6 month intervals starting at 3 months until
30 months. Hypothyroidism was defined as an elevated
TSH value based on the reference value given for each
type of TSH test (TSH only (0.20–4.00 mU/L) or Pro-
gressive TSH (0.30–4.00 mU/L).
Follow-up
All patients were followed at regional cancer treatment
centers at regular intervals following treatment. Our cut
off time point was February 1st, 2015. Patients who were
suspected to have disease recurrence underwent a meta-
static workup including appropriate imaging, endoscopy
and biopsy as per standard of care.
Statistical analysis
Baseline characteristics were compared using standard
modes of comparison. Continuous data was analyzed
using analysis of variance (ANOVA). Categorical data
was compared using the chi-squared test. Univariate
analysis was performed to determine the prevalence of
hypothyroidism and the optimal timing of the elevation
of TSH. Analyses were performed using SPSS Statistics
20.0 (SPSS Inc, Chicago, IL).
Results
One hundred and sixty two patients were diagnosed
with ES-LSCC in Alberta from 2008 to 2013. Of these,
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67 patients were excluded: 11 for insufficient data
points, 8 patients were treated with primary surgery and
48 patients had an elevated TSH prior to the start of RT
treatment. Exclusion criteria were then applied to inclu-
sion criteria, leading to a final data set of 95 patients for
analysis.
Figure 1 represents overall and disease-free survival
for our ES-LSCC data set. Five-year overall and disease-
free survivals were 79 and 81 % respectively.
Table 1 contains patient demographic and tumour
subsites information. The average age was 66.1 years
(range: 41.0–88.0 years) with a strong male predomin-
ance (82.3 %). Glottis was the most common tumor sub-
site (77.9 %), followed by subglottis (14.7 %). A minority
of cases were represented by supraglottis and transglottis
subsites at 4.2 and 3.2 % respectively.
Tables 2 shows TSH specific data. Forty five (46.9 %)
of patients had elevated TSH during the period of follow
up. In addition, 27 patients were found to have a TSH
greater than 10.00 mU/L. Figure 2 shows the breakdown
in terms of time to elevated TSH. The majority of pa-
tients (42 %) had elevated TSH at the 12-month interval.
Seventy six of 95 (80.0 %) and 79 of 95 patients
(83.2 %) received TSH testing within the first 15 and
18 months following initiation of RT. Of the 19 patients
not receiving TSH testing during the first 15 months fol-
lowing treatment 6 patients presented with elevated
TSH values upon first TSH testing. Figure 3 illustrates
the distribution and frequency of TSH screening. Test-
ing started at 3 month and was continued through
30 months after completion of RT treatments. The
majority of TSH testing took place within the first
21 months. For TSH levels tested at 3, 6, 9, 12, 15, 18
and 21 months the frequency of patients tested was
greater than 50 % for all intervals (56.8, 66.3, 60.0, 67.4,
66.3, 60.0 and 56.8 %) respectively. From 24 to
30 months between 36.8 and 42.1 % of patients received
TSH screening. A standard error calculation was per-
formed for this data with a value of 0.44. The single
greatest screening interval was at 12 months, where
67.4 % of patients had TSH testing. The lowest screening
interval was at 24 months with 36.8 % of patients tested.
Fig. 1 a Overall Survival, b Disease-Free Survival rates for patients with stage I or II laryngeal cancer
Table 1 Patient characteristics
Variable N
n 95




Mean CCI (range) 2.8 (0.0–13.0)








CCI Charlson comorbidity index
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Discussion
It is well established that treatment of HNC using RT,
chemotherapy or surgery increases the risk of developing
hypothyroidism. Based on the literature, compared to
other treatments modalities for ES-LSCC, RT is associ-
ated with the greatest risk, 48 % at 5 years and 67 % at
8 years following treatment [15]. Its pathophysiology is
not completely understood, but most likely involves
damage to thyroid vasculature. Additional theories spe-
cific to RT involve direct micro and macrovascular dam-
age, fibrosis of the thyroid capsule which may limit
compensatory thyroid enlargement and even the forma-
tion of induced antithyroglobulin antibodies [7]. The risk
of developing hypothyroidism becomes greater the
closer the anatomical relationship between the treated
tissue and thyroid tissue [16]. Despite this high inci-
dence, no study has looked at hypothyroidism in patients
who receive single modality therapy with RT for ES-
LSCC. As such, there are currently no standardised post
treatment hypothyroidism screening recommendations
specifically for this patient population.
The literature has yielded multiple studies investigat-
ing the effects of RT in the treatment of HNC and LSCC
within a heterogeneous patient population. Two of the
most relevant studies are discussed. A systematic review
published in 2011 by Boomsma et al. [17] looking at the
incidence of hypothyroidism in all presentations of HNC
treated with RT cited rates of subclinical hypothyroidism
from 23 to 53 % at median follow up times of 2.4 to
6.1 years post RT. They found that hypothyroidism de-
veloped at a median interval of 1.4 to 1.8 years after
treatment. The paper suggests that the development of
subclinical hypothyroidism found at median follow up
times should act as an indicator for the duration of TSH
monitoring following treatment. However, no follow up
regime or optimal time to initiate screening was sug-
gested. The study by Kumar et al. [18] is the best ex-
ample of a population similar to the one we examined.
They looked at all curative treatment modalities includ-
ing RT, surgery as well as chemoradiotherapy (CRT) for
ES-LSCC and found rates of subclinical hypothyroidism
at 24 % and symptomatic hypothyroidism at 6 %. Unfor-
tunately, they were unable to provide information re-
lated to timing of onset of hypothyroidism post RT.
Table 2 Hypothyroidism variables
Variable N
Elevated TSH, no. (%) 45 (46.9)
Mean Peak TSH (range), mIU/mL 16.9 (4.0–55.9)
Number of Patients TSH > 10 mU/L 27
TSH Thyroid stimulating hormone
Fig. 2 Patients with TSH Greater than 4.00 mU/L by Time of Presentation
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Information in relation to the length of follow up was
also insufficient as a result of limited access to patient
TSH results and follow up clinical information. In com-
parison, we found 46.9 % of our study group developed
elevated TSH following treatment with RT. This is most
commonly observed at the 12 month mark with 89.4 %
of patients whom developed and elevated TSH at or
after this time point.
Screening for hypothyroidism with TSH is reliant on a
normal functioning hypothalamic–pituitary–thyroid axis.
The use of TSH is cheap, reliable and sensitive to fluctu-
ations in thyroxine (T4) levels [9]. Our study used TSH
as a marker for hypothyroidism, identifying cases of thy-
roid gland dysfunction. Subclinical hypothyroidism (mild
thyroid gland failure) is defined as persistently elevated
TSH with normal thyroxine (T4) levels over a period of
at least 3 months. Overt hypothyroidism relies on a per-
sistently elevated TSH with low T4 levels [19]. Pro-
longed elevation of TSH levels correlate with significant
long term sequelae. Increased total low-density lipopro-
tein cholesterol and cardiac morbidity including mortal-
ity and atherosclerotic events are among the most severe
[10]. Therefore, thyroid hormone replacement therapy is
recommended in all cases where TSH is > than 10 mIU/L
[9]. Given the strong correlation between TSH values and
significant long term sequelae, at our institution, the use
of TSH alone suffices in determining need for treatment
as well as for use as a maker of thyroid dysfunction.
Utilizing TSH ensured sufficient data for collection
and ease of comparison from one institution to another.
Reference ranges for elevated TSH varied depending on
institution or type of test (progressive TSH or TSH
only). All elevated TSH tests were categorized as
hypothyroidism as measured by reference ranges for
each test. We obtained mean peak TSH values of 16.9
mIU/L (4.0–55.9 mIU/L) in our population indicating a
need for thyroxine replacement to avoid long term se-
quelae. Status and treatment of clinical versus sublinical
hypothyroidism was beyond the scope of our study.
Within our patient cohort, access to TSH information
was more reliable than T3/T4 which was not routinely
done as part of the hypothyroidism work up. Addition-
ally, a protocol for treating subclinical versus clinical
hypothyroidism is still not well defined. From the litera-
ture, a study looking at presentations of subclinical
versus biochemical hypothyroidism in 2 randomized
controlled trials by Murthy et al. [20] examined 122
patients affected by head and neck cancers treated with
3D conformational RT. They measured TSH and T4
levels every 3 to 6 months following completdraw ion
of treatment. Patients with elevated TSH alone were
deemed subclinical hypothyroidism and patients with
elevated TSH and low T4 levels were classified as bio-
chemical hypothyroidism. Hypothyroidism presented in
55 % of patients at a median follows up of 44 months, of
these 39.3 % subclinical and 15.7 % biochemical. As de-
scribed by the author, the decision to treat patient was not
based on T4, rather treatment initiation was based on
presentation with symptoms of hypothyroidism or pro-
longed elevation of TSH. This is in keeping with the litera-
ture. A TSH level greater or equal to 10 mIU/L for a
period longer than 3 months is deemed significant enough
Fig. 3 Percentage of Patients Receiving TSH Testing at Given Time Intervals
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to initiate thyroid hormone replacement therapy in order
to obviate long term consequences. Therefore for our own
population of ES-LSCC treated with RT, TSH was utilized
alone as the cut-off point to avoid long term sequelae.
Based on our results, the optimal time to initiating
screening for hypothyroidism is at 12 months. We ob-
served a significant peak at this time point represented
by 20 cases (42.6 %). The earliest elevated TSH was
noted at 3 month in a minority of cases (2.1 %). It
should be noted the majority of patients presented with
elevation of TSH at or after 12 months (87.3 %). The
incidence of elevated TSH in the Albertan ES-LSCC
population was 45 patents (46.9 %). We found evidence
that thyroid function worsens with time, the mean peak
TSH was observed at 26.6 months with an average TSH
value of 16.9 mIU/L. The delay in presentation in peak
TSH is likely explained by a combination of factors. Thy-
roid stimulating hormone values greater than 4 mIU/L
and less than 10 mIU/L are indeterminate in terms of ini-
tiating treatment [9]. The onset of hypothyroidism follow-
ing RT is insidious and increases significantly with time
following treatment [15]. Likely, the development of TSH
level greater than 10mIU/L appeared more frequently at a
greater duration of time following RT. Also, time for treat-
ment optimization and patient compliance with treatment
(routinely elevated TSH levels do not produce symptom-
atology) may contribute to the delay in peak TSH values.
Given that our study indicates a peak TSH a later time
point than the first observed elevation of TSH and that
the risk of developing hypothyroidism increases with time
following treatment. This may reinforce the need for life-
long TSH screening. Not only to pick up hypothyroidism
initially but to titrate treatments appropriately.
Limitations of the study are acknowledged. The pro-
spectively collected, retrospectively reviewed population-
based design of the study did not allow for controls. No
set protocol for TSH screening following RT is in place
throughout Alberta. Although patients generally receive
screening in an every 6–12 month fashion the number
of screening events are at the discretion of the family
physician, radiation or surgical oncologist. The majority
of screening took place between 3 and 21 months. At
each of these time intervals greater than 50 % of patients
received screening (Fig. 3), a good indication that
although no explicit screening regime is implemented,
the majority of patients received routine investigation
for hypothyroidism. Screening tapered after 21 months
with between 36.8 and 42.1 % patients being screened
between 24 and 30 months. Additionally, we were only
able to consistently access TSH results, consequently
without T4 results we were unable to definitively classify
patients into categories of subclinical versus overt
hypothyroidism. Even without T4 information available
TSH information was able to indicate the need for
treatment in our ES-LSCC population. Our study also
lacked fields of RT therapy for individual patients, while
this may have led to confounding of data, all patients
were staged at T1/2 and N0 with standardized curative
RT protocol as per the Division of Radiation Oncology
at the Cross Cancer Institute, University of Alberta.
Given these limitations a multi-institutional, prospectively
planned study utilizing a set hypothyroidism screening
regime—including TSH and T4 monitoring at set time
intervals—would be useful to determine whether
hypothyroid screening protocols affect patient outcomes.
Conclusion
Hypothyroidism in patients with ES-LSCC treated with
curative RT is common. This population-based study sug-
gests that optimal timing for screening for hypothyroidism
using TSH is at 12 months’ time. Future prospective studies
to develop screening protocols for hypothyroidism in
patients with ES-LSCC treated with curative RT should be
undertaken.
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